FAQ on TransCode Therapeutics' Appointment of RNAi Pioneer Phillip Zamore to Its Scientific Advisory Board
Summary
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has appointed Dr. Phillip D. Zamore, a renowned RNA interference (RNAi) researcher, to its Scientific Advisory Board, enhancing its RNA-targeted cancer therapy programs.
Who is Dr. Phillip D. Zamore?
Dr. Phillip D. Zamore is a leading figure in RNA interference (RNAi) research, co-founder of Alnylam Pharmaceuticals, and currently the Chair of the RNA Therapeutics Institute at UMass Chan Medical School. His foundational work in RNA biology and gene silencing mechanisms has earned him election to the National Academy of Sciences and other prestigious institutions.
Why is Dr. Zamore’s appointment to TransCode’s Scientific Advisory Board significant?
Dr. Zamore’s appointment is significant because his expertise in RNAi research and gene silencing mechanisms will strategically enhance TransCode Therapeutics’ RNA-targeted cancer therapy programs, potentially accelerating the development of innovative treatments for metastatic cancer.
What is TransCode Therapeutics focused on?
TransCode Therapeutics is a clinical-stage oncology company focused on treating metastatic disease through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform.
What is TransCode’s lead therapeutic candidate?
TransCode’s lead therapeutic candidate is TTX-MC138, which is focused on treating metastatic tumors that overexpress microRNA-10b, a unique biomarker of metastasis.
Where can I find more information about TransCode Therapeutics?
More information about TransCode Therapeutics (NASDAQ: RNAZ) is available in the company’s newsroom at https://ibn.fm/RNAZ.
What is BioMedWire?
BioMedWire is a specialized communications platform focusing on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors, part of the Dynamic Brand Portfolio @ IBN, which provides comprehensive corporate communications solutions.
How can I view the full press release about Dr. Zamore’s appointment?
The full press release can be viewed at https://ibn.fm/03LbD.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 111296